CA2063400A1 - Inhibition de la voie correspondant a la regle de l'extremite n-terminale dans les cellules vivantes - Google Patents

Inhibition de la voie correspondant a la regle de l'extremite n-terminale dans les cellules vivantes

Info

Publication number
CA2063400A1
CA2063400A1 CA2063400A CA2063400A CA2063400A1 CA 2063400 A1 CA2063400 A1 CA 2063400A1 CA 2063400 A CA2063400 A CA 2063400A CA 2063400 A CA2063400 A CA 2063400A CA 2063400 A1 CA2063400 A1 CA 2063400A1
Authority
CA
Canada
Prior art keywords
amino
protein
terminal
compositions
terminal residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2063400A
Other languages
English (en)
Other versions
CA2063400C (fr
Inventor
David K. Gonda
Rohan T. Baker
Alexander Varshavsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2063400A1 publication Critical patent/CA2063400A1/fr
Application granted granted Critical
Publication of CA2063400C publication Critical patent/CA2063400C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Fats And Perfumes (AREA)

Abstract

Méthode pour agir sur la stabilité métabolique d'une protéine intracellulaire in vivo (dans des cellules intactes et dans des animaux entiers) et compositions pour conditionner une telle régulation. Cette méthode comporte l'administration d'un régulateur ayant un résidu d'acide aminé N-terminal identique ou similaire au résidu N-terminal d'une protéine ou d'un groupe de protéines intracellulaires. Au besoin, ce résidu N-terminal est choisi comme membre d'une catégorie destabilisatrice de résidus en position N-terminale, suivant la règle de dégradation des protéines à partir de l'extrémité N. Les compositions peuvent comprendre un construit d'ADN codant une protéine et un construit d'ADN codant un régulateur ayant un résidu N-terminal identique ou similaire à la protéine. Parmi les compositions, on peut également retrouver le régulateur, qui possède un résidu N-terminal identique ou similaire au résidu N-terminal de la protéine et qui, si l'on veut, fait partie de la catégorie destabilisatrice de résidus en position N-terminale, suivant la règle de dégradation des protéines à partir de l'extrémité N. Les méthodes et compositions peuvent servir à traiter des maladies causées par une dégradation anormale d'une protéine ou d'un groupe de protéines donnés et à améliorer la production in vivo d'une protéine ou d'un groupe de protéines donnés dans des applications biotechnologiques.
CA002063400A 1989-06-30 1990-06-27 Inhibition de la voie correspondant a la regle de l'extremite n-terminale dans les cellules vivantes Expired - Fee Related CA2063400C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37382589A 1989-06-30 1989-06-30
US373,825 1989-06-30

Publications (2)

Publication Number Publication Date
CA2063400A1 true CA2063400A1 (fr) 1990-12-31
CA2063400C CA2063400C (fr) 1997-07-15

Family

ID=23474039

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002063400A Expired - Fee Related CA2063400C (fr) 1989-06-30 1990-06-27 Inhibition de la voie correspondant a la regle de l'extremite n-terminale dans les cellules vivantes

Country Status (10)

Country Link
US (1) US5766927A (fr)
EP (1) EP0479912B1 (fr)
JP (1) JP2904921B2 (fr)
AT (1) ATE106449T1 (fr)
AU (1) AU5963290A (fr)
CA (1) CA2063400C (fr)
DE (1) DE69009476T2 (fr)
DK (1) DK0479912T3 (fr)
ES (1) ES2054365T3 (fr)
WO (1) WO1991000356A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861312A (en) * 1997-12-02 1999-01-19 California Institute Of Technology Nucleic acid encoding mammalian UBR1
AU2605600A (en) * 1999-01-11 2000-08-01 Mindset Biopharmaceuticals (Usa) Inc. Methods for regulating the stability of recombinant proteins and products usefultherein
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
WO2000050089A2 (fr) * 1999-02-26 2000-08-31 Mindset Biopharmaceuticals (Usa) Ltd. Regulation de la stabilite de proteines de recombinaison, anticorps et produits convenant pour cette regulation
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
WO2004058157A2 (fr) * 2002-12-16 2004-07-15 Globeimmune, Inc. Vaccins a base de levure pour immunotherapie
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2008039483A2 (fr) * 2006-09-26 2008-04-03 Massachusetts Institute Of Technology Peptides auto-assemblés modifiés
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US8530636B2 (en) * 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
WO2011088421A2 (fr) * 2010-01-15 2011-07-21 California Institute Of Technology Découverte et applications de la fonction protéolytique de l'acétylation n-terminale des protéines cellulaires
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2021216621A2 (fr) 2020-04-20 2021-10-28 Vestaron Corporation Polypeptides variants d'u1-agatoxine-ta1b stables à la protéolyse pour la lutte antiparasitaire
AU2021265277A1 (en) 2020-05-01 2022-12-08 Vestaron Corporation Insecticidal combinations
IL307293A (en) 2021-04-01 2023-11-01 Vestaron Corp AV3 mutant polypeptides for pest control
IL313184A (en) 2021-11-29 2024-07-01 Ironwood Pharmaceuticals Inc Medicinal preparations for the treatment of visceral pain
WO2023122805A1 (fr) 2021-12-20 2023-06-29 Vestaron Corporation Procédé de pression de sélection par sorbitol
AR129351A1 (es) 2022-05-18 2024-08-14 Vestaron Corp Variantes de péptidos pesticidas actx
WO2023245100A1 (fr) 2022-06-17 2023-12-21 Vestaron Corporation Peptides variants de ncr13 antimicrobiens
WO2024026406A2 (fr) 2022-07-29 2024-02-01 Vestaron Corporation Peptides actx de nouvelle génération

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512979A (en) * 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
US4514391A (en) * 1983-07-21 1985-04-30 E. R. Squibb & Sons, Inc. Hydroxy substituted peptide compounds
US4551445A (en) * 1983-10-14 1985-11-05 The Medical College Of Ohio Derivatives of arginine vasopressin antagonists
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
EP0324789B1 (fr) * 1986-10-02 2003-08-20 Massachusetts Institute Of Technology Procede de regulation de la stabilite metabolique de proteines
US5108919A (en) * 1988-06-24 1992-04-28 Genentech, Inc. Dna sequences encoding yeast ubiquitin hydrolase
CH680013A5 (fr) * 1988-09-19 1992-05-29 Mathias Och

Also Published As

Publication number Publication date
WO1991000356A1 (fr) 1991-01-10
JPH04506298A (ja) 1992-11-05
JP2904921B2 (ja) 1999-06-14
EP0479912A1 (fr) 1992-04-15
ES2054365T3 (es) 1994-08-01
DE69009476D1 (de) 1994-07-07
DK0479912T3 (da) 1994-10-10
AU5963290A (en) 1991-01-17
US5766927A (en) 1998-06-16
DE69009476T2 (de) 1994-12-22
CA2063400C (fr) 1997-07-15
EP0479912B1 (fr) 1994-06-01
ATE106449T1 (de) 1994-06-15

Similar Documents

Publication Publication Date Title
CA2063400A1 (fr) Inhibition de la voie correspondant a la regle de l'extremite n-terminale dans les cellules vivantes
AU694104B2 (en) Compositions containing corneocyte proteins
Hille et al. Tyrosine sulfation: a post‐translational modification of proteins destined for secretion?
EP2298355A3 (fr) Protéines de fusion d'albumine
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
ES8707974A1 (es) Procedimiento para la obtencion de un peptido
CA2161808A1 (fr) Compositions bmp-10
DE68916932D1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
AU6444190A (en) A polypeptide
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996028470A3 (fr) Analogues peptidiques de proteine de base de myeline utile dans le traitement de la sclerose en plaques
BG104267A (en) Aminoterminally incised rantes as haemokin antagonists
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
BR9304205A (pt) Extrato à base de proteínas bacterianas, processo para preparação do extrato, e composição farmacêutica
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
EP0297362A3 (fr) Aprotinine humaine dont le reste Lys en 15 est substitué par un autre reste protogène d'amino-acide
ES2170144T3 (es) Variantes que no se empalman de gp350/220.
AUPM772494A0 (en) Improvements in production of proteins in host cells
WO2000006706A3 (fr) Phosphatase mutante de proteine-kinase associee aux membranes
HUT52117A (en) Process for producing amblyommin and process for producing pharmaceutical compositions comprising such compound as active ingredient
HU0102043D0 (en) Pharmaceutical compounds which interact with an ca2+ channel alpha2delta subunit
DE10033195A1 (de) Bifunktionale Fusionsproteine aus Hirudin und TAP
WO2003002598A3 (fr) Peptides destines a etre utilises en tant que facteurs de translocation
WO2002085305A3 (fr) Compositions et methodes pouvant induire la mort de cellules cancereuses

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed